Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial

BACKGROUND: Advanced biliary tract cancer (ABC) has a poor prognosis. Cediranib, in addition to cisplatin/gemcitabine [CisGem], improved the response rate, but did not improve the progression-free survival (PFS) in the ABC-03 study. Minimally invasive biomarkers predictive of cediranib benefit may i...

Descripción completa

Detalles Bibliográficos
Autores principales: Backen, Alison C., Lopes, Andre, Wasan, Harpreet, Palmer, Daniel H, Duggan, Marian, Cunningham, David, Anthoney, Alan, Corrie, Pippa G., Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J., Waters, Justin S., Steward, William P., Rees, Charlotte, McNamara, Mairéad G., Beare, Sandy, Bridgewater, John A., Dive, Caroline, Valle, Juan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035166/
https://www.ncbi.nlm.nih.gov/pubmed/29925934
http://dx.doi.org/10.1038/s41416-018-0132-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035166/
https://www.ncbi.nlm.nih.gov/pubmed/29925934
http://dx.doi.org/10.1038/s41416-018-0132-8

Ejemplares similares